Slow Capital Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,785 shares of the company’s stock after purchasing an additional 621 shares during the period. Slow Capital Inc.’s holdings in Johnson & Johnson were worth $2,089,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of JNJ. Taylor & Morgan Wealth Management LLC increased its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the stock company’ valued at $635,000 after purchasing an additional 57 shares during the last quarter. Red Wave Investments LLC lifted its holdings in shares of Johnson & Johnson by 2.0% in the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the stock 0 acquiring an additional 59 shares during the last quarter. Argus Investors Counsel Inc. boosted its stake in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,9 an additional 61 shares in the last quarter. Alta Capital Management LLC raised its position in Johnson & Johnson by 0.4% in the 2nd quarter. Alta Capital M management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after purchasing an additional 61 shares during the period. Finally, Paces Ferry Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 0.7% Paces Ferrys during Adverts third. LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after buying an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Johnson & Johnson stock opened at $173.43 on Friday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The business’s fifty day simple moving average is $176.32 and its two-hundred day simple moving average is $171.51. The company has a market capitalization of $453.43 billion, a price-to-earnings ratio of 24.15, a price-to-earnings -growth ratio of 3.29 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the company earned $2.60 per sharing . The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend ex yield of 2.61%. -dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Barclays initiated coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective for the company. Sanford C. Bernstein reduced their target price on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Citigroup lifted their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven equities research analysts have rated the stock with a hold rating, four have as signed a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $182.42.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. com Follow the transaction, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP 8 Peter Fasolo 6 of the company’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now owns 114,676 shares in the valued company, at $18,864,202. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock k in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the transaction, the executive vice president now directly owns 126,456 shares in valued at the company, $22,354,891.68. The disclosure for this sale can be found here. Insiders have sold 300,750 shares of company stock valued at $52,311,677 over the last ninety days. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby INTER ISTER brands; oral care under the Lbrs skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here